Dalton Medicinal Chemistry will utilize their proprietary insights to design and synthesize several novel classes of compounds against selected riboswitch targets. BioRelix will advance these compounds using their biological assays and knowledge of RiboSwitch drug discovery and development.
Brian Dixon, CEO of BioRelix, said: “We are pleased to have the opportunity to work with the creative team at Dalton Medicinal Chemistry in the discovery of new entities for treating infectious diseases. Their expertise, coupled with our proprietary and leading position in RiboSwitch technology will lead to important new medicines.”